TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19159590
Drug: KIR2DL1 HLA-C2
Normalized name: Gentamicin C2
DrugBank: Gentamicin C2 (DB17884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KIR2DL1 HLA-C2 combination in CD patients (0.411)
Study: 16432469
Drug: Thick, low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thick, low water content, soft contact lens fitted under a light patch to one eye of diabetic patients
Study: 16432469
Drug: Thick, low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thick, low water content, soft contact lens fitted under a light patch to one eye of nondiabetic control subjects
Study: 9685963
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms Heberbiovac-HB vaccine
Study: 9685963
Drug: 5 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 micrograms Heberbiovac-HB vaccine
Study: 8314499
Drug: Interferon alfa‐2b,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2b, 3 million units (MU) subcutaneously thrice weekly for four months
Study: 2876497
Drug: Somatostatin (native
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (native hormone)
Study: 22525048
Drug: Tofacitinib 0.001%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 0.001% twice daily (n = 47)
Study: 22525048
Drug: Tofacitinib 0.005%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 0.005% twice daily (n = 48)
Study: 22525048
Drug: Tofacitinib 0.005%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 0.005% once daily (n = 44)
Study: 22525048
Drug: Cyclosporine 0.05%
Normalized name: CYCLOSPORINE 0.05% (PF) EMULSION,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 0.05% twice daily (n = 47)
Study: 22525048
Drug: Tofacitinib 0.005%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 0.005% once daily
Study: 24299727
Drug: G‐CSF group
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF group
Study: 19056135
Drug: After withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: After withdrawal of G‐CSF
Study: 16339790
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 4 mg kg(‐1) h(‐1) (Group P‐4)
Study: 16339790
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 6 mg kg(‐1) h(‐1) (Group P‐6)
Study: 10826412
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (300 mg/day)
Study: 1499473
Drug: 0.2 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 U/kg body wt NPH insulin
Study: 1499473
Drug: 1.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/day metformin
Study: 20973744
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (lutein 3.2 mg, L-glutathione 5 mg, vitamin E 15 IU, vitamin C 150 mg, zinc 40 mg, copper 2 mg, selenium 40 mcg, manganese 5 mg) administered once a day for 3 months.
Study: 12059890
Drug: Inguinal field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inguinal field block (IFB) with ropivacaine (50-60 ml, 5 mg/ml) before surgery
Study: 7779538
Drug: Antioxidant therapy
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant therapy (AOT)
Study: 7779538
Drug: Conditioning therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioning therapy
Study: 26914986
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + 10% E. officinalis gel application
Study: 29981205
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + placebo gel
Study: 9616313
Drug: R093877 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: R093877 1 mg
Study: 9616313
Drug: R093877 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: R093877 2 mg
Study: 2508213
Drug: Enprostil 7
Normalized name: enprostil
DrugBank: Enprostil (DB13824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprostil 7 micrograms twice daily
Study: 2508213
Drug: Aspirin 500
Normalized name: aspirin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 500 mg four times a day
Study: 30103299
Drug: Deep heating
Normalized name: Mentholatum Deep Heating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep heating therapy (DHT) via MF diathermy (450 KHz)
Study: 30103299
Drug: Superficial heating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superficial heating therapy (SHT) via electric resistance
Study: 22905853
Drug: Tadalafil 10
Normalized name: tadalafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 10 mg and 20 mg
Study: 21807638
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Adjuvant!Online, quantitative ER, Ki67, and treatment with EP
Study: 18799004
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (maintaining glucose levels between 80 and 110 mg/dl)
Study: 18799004
Drug: Standard insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin therapy (maintaining glucose levels between 180 and 200 mg/dl)
Study: 16779924
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections (IG) - 5 x 2 mL over 10 days
Study: 16779924
Drug: Oral tablets
Normalized name: digoxin 0.1875 MG Oral Tablets
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablets (OG) - one tablet daily for 30 days
Study: 9600821
Drug: RT with
Normalized name: NuCort with Aloe
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT with infusional IV 5‐FU 1g/m2 daily in the first and last 4 days of RT
Study: 9600821
Drug: Partially hyperfractionated
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially hyperfractionated RT with concurrent 5‐FU
Study: 3048235
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (1 mg/kg bodyweight) given 20 min prior to infusion of intravenous immunoglobulin.
Study: 31460865
Drug: Contingency Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency Management (CM) intervention with financial incentives (shopping vouchers) for cannabis abstinence over 12 once-weekly sessions, confirmed using urinalysis. Maximum value of vouchers: £240.
Study: 31460865
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm receiving treatment as usual only.
Study: 25668262
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (10 g/d)
Study: 10931081
Drug: 2 IU/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 IU/d sc human recombinant growth hormone for a mean of 14 weeks
Study: 30212555
Drug: Alternative package
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative package leaflets (drug facts box with/without reading instruction, narrative format with numbers)
Study: 23166914
Drug: IPARZINE‐4A‐SKR topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPARZINE‐4A‐SKR topical agent
Study: 20088409
Drug: GABA drink
Normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABA drink (1000 mg of GABA)
Study: 20088409
Drug: Placebo (sports
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sports drink of 200 mL)
Study: 16544102
Drug: PSTE (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSTE (2.5 g)
Study: 16544102
Drug: PSTA (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSTA (2.5 g)
Study: 7910127
Drug: Levosulpiride 25
Normalized name: Levosulpiride 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosulpiride 25 mg 3 times daily for 30 days
Study: 7910127
Drug: Domperidone 10
Normalized name: domperidone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 10 mg 3 times daily for 30 days
Study: 28213593
Drug: VVZ-149 with
Normalized name: Vvz-149 free base
DrugBank: Opiranserin (DB16271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VVZ-149 with intravenous (IV) hydromorphone patient-controlled analgesia (PCA)
Study: 21741804
Drug: High-dose hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose hydrocortisone (100-140 mg)
Study: 15324486
Drug: TJ-29 (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ-29 (3.0 g thrice daily for 7 days)
Study: 11227677
Drug: OAC-I (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC-I (6 weeks of 'A' formulation of omeprazole [20 mg twice daily] plus 2 weeks of amoxicillin [1.0 g twice daily] and clarithromycin [500 mg twice daily])
Study: 11227677
Drug: OAC-II (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC-II (6 weeks of 'B' formulation of omeprazole [20 mg twice daily] plus 2 weeks of the same antibiotics)
Study: 9286938
Drug: xemilofiban 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: xemilofiban 10 mg P.O. BID or higher
Study: 9286938
Drug: placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (250 mg ticlopidine P.O. BID)
Study: 8326539
Drug: Routine appropriate
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine appropriate treatment (may include 3000 units vitamin A per day)
Study: 31992840
Drug: Post-induction chemotherapy
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-induction chemotherapy regimens
Study: 25425058
Drug: lercanidipine 20
Normalized name: lercanidipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lercanidipine 20 mg/day
Study: 24352340
Drug: amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine 10 mg/day
Study: 16329161
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (120 mg per day)
Study: 9203669
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated varicella vaccine (3625 pfu)
Study: 9203669
Drug: Partially heat-inactivated
Normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially heat-inactivated vaccine (1125 pfu)
Study: 9203669
Drug: Partially heat-inactivated
Normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially heat-inactivated vaccine (439 pfu)
Study: 27749154
Drug: RTP+Myomo therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTP+Myomo therapy (repetitive task-specific practice with myoelectric brace)
Study: 25748612
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (specific trials: JUPITER and ASCOT for primary prevention; CARE and PROVE IT‐TIMI 22 for secondary prevention)
Study: 25748612
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (specific trials: JUPITER and ASCOT for primary prevention)
Study: 21878743
Drug: Bolus rapid-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus rapid-acting insulin analogues
Study: 18640810
Drug: Partial breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial breast irradiation with high-dose-rate brachytherapy (4 Gy twice a day for 4 days, total dose 32 Gy)
Study: 15957245
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (20 g/day for 5 days)
Study: 12145915
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.4 mg/kg BW
Study: 12145915
Drug: Rectal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rectal midazolam 0.3 mg/kg BW
Study: 11913409
Drug: Estrone sulfate
Normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estrone sulfate 1.25 mg + MPA 2.5 mg
Study: 11913409
Drug: Estrone sulfate
Normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estrone sulfate 1.25 mg + MPA 5.0 mg
Study: 11913409
Drug: Estrone sulfate
Normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estrone sulfate 1.25 mg + MPA 10 mg
Study: 2685142
Drug: OK-432 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: OK-432 (5 KE, administered by intramuscular injection every other day for up to 5 years)
Study: 31093662
Drug: Heparin dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin dose <70 U/kg
Study: 31093662
Drug: Heparin dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin dose 70-100 U/kg
Study: 31093662
Drug: Heparin dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin dose >100 U/kg
Study: 31472360
Drug: Wireless CRT
Normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wireless CRT system (therapy on)
Study: 31472360
Drug: Sham control
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham control (therapy off)
Study: 27933333
Drug: BCF indices
Normalized name: Hemidesmus indicus root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCF indices (I30/I0, CP30/CP0, ΔI30/ΔG30, ΔCP30/ΔG30, corrected insulin response at 30 min) for incident type 2 diabetes
Study: 23842141
Drug: HDL levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDL levels <40 mg/dL
Study: 23842141
Drug: HDL levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDL levels >40 mg/dL
Study: 23842141
Drug: HDL levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDL levels >60 mg/dL
Study: 22187278
Drug: Chlorthalidone-based stepped-care
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone-based stepped-care therapy (active treatment)
Study: 19301378
Drug: Other agents
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other agents (cyclophosphamide, rituximab, azathioprine, cyclosporine, interferons, fludarabine, mycophenolate mofetil, etanercept)
Study: 16269179
Drug: Prednisolone (1mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (1mg/kg/day for 10 days, followed by tapering over 4 days)
Study: 16269179
Drug: Placebo (anti-epileptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (anti-epileptic monotherapy)
Study: 24002213
Drug: Celecoxib 100
Normalized name: celecoxib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 100 mg twice a day
Study: 3896662
Drug: Tenoxicam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam (40 mg/day)
Study: 3896662
Drug: Piroxicam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (40 mg/day)
Study: 25543612
Drug: Sonic endo‐instruments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonic endo‐instruments in combination with Mtwo Ni‐Ti files
Study: 12207774
Drug: oral allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral allopurinol (15 mg/kg/day) for 3 weeks
Study: 12207774
Drug: intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular injection of Glucantime (30 mg/kg/day) for 2 weeks
Study: 12207774
Drug: combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined therapy with allopurinol plus Glucantime
Study: 9579010
Drug: Counseling +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling + Active Nicotine Patch (CAP)
Study: 9579010
Drug: Counseling +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling + Placebo Patch (CPP)
Study: 320917
Drug: clemastine fumarate
Normalized name: Clemastine Fumarate
DrugBank: Clemastine (DB00283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clemastine fumarate 2.68 mg
Study: 320917
Drug: chlorpheniramine 4
Normalized name: chlorpheniramine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: chlorpheniramine 4 mg
Study: 29061540
Drug: Normal prostate
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal prostate specific antigen (<2 ng/ml)
Study: 29061540
Drug: Elevated prostate
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated prostate specific antigen (≥3 ng/ml)
Study: 29061540
Drug: Equivocal prostate
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equivocal prostate specific antigen (2-3 ng/ml)
Study: 16644630
Drug: Deltec Cozmo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deltec Cozmo insulin pump with meal bolus alarms (experimental group)
Study: 16644630
Drug: Current insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current insulin pumps without meal bolus alarms (control group)
Study: 12806326
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (specimens without additional surface treatments)
Study: 8976723
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids without acyclovir
Study: 8976723
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids and oral acyclovir
Study: 1535485
Drug: Isoflurane 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflurane 1% and alfentanil 10 micrograms.kg‐1 as a bolus and 10 micrograms.kg‐1.h‐1 infusion (group IA)
Study: 1535485
Drug: Propofol 9
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 9 mg.kg‐1.h‐1 infusion decreasing to 6 mg.kg‐1.h‐1 and alfentanil 10 micrograms.kg‐1.h‐1 (group PA)
Study: 6747766
Drug: Atropine 0.01
Normalized name: atropine 0.0194 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.01 mg/kg plus Pancuronium 0.1 mg/kg
Study: 6747766
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (controls)
Study: 22381949
Drug: moclobemide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: moclobemide (400 mg)
Study: 22381949
Drug: clomipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: clomipramine (150 mg)
Study: 16208798
Drug: Oral‐B ProfessionalCare
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B ProfessionalCare 7000 (PC 7000)
Study: 12439787
Drug: Estradiol 2
Normalized name: estradiol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 2 mg daily for three months
Study: 12439787
Drug: Estradiol 2
Normalized name: estradiol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 2 mg continued for another nine months with medroxyprogesterone for ten days every three months
Study: 10080612
Drug: Topotecan (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (1.5 mg/m2, 30-minute infusion daily for 5 days every 21 days)
Study: 10080612
Drug: CAV (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAV (cyclophosphamide 1,000 mg/m2, doxorubicin 45 mg/m2, vincristine 2 mg, infused on day 1 every 21 days)
Study: 2248508
Drug: Cyclophosphamide for
Normalized name: Cyclophosphamide for Injection
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide for eight weeks (2 mg/kg/day)
Study: 2248508
Drug: Cyclophosphamide for
Normalized name: Cyclophosphamide for Injection
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide for twelve weeks (2 mg/kg/day)
Study: 31847536
Drug: Varenicline (smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (smoking cessation treatment)
Study: 28105737
Drug: Twice-daily tooth
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily tooth brushing with a rotating-oscillating power toothbrush (Oral-B Professional Care 1000™)
Study: 23466649
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF), 300 mg orally per day
Study: 15682845
Drug: Intravenous regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous regional blockade therapy consisting of dexamethasone and lidocaine
Study: 9582556
Drug: Oral daily
Normalized name: Summer's Eve Sheer Floral Daily Cloths
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily calcitriol 0.5 micrograms/die (Treatment A)
Study: 9582556
Drug: Three oral
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three oral boluses of 2 micrograms of calcitriol a week (Treatment B)
Study: 9582556
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral bolus of 2 micrograms of calcitriol a week (Treatment C)
Study: 9582556
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (15 patients, mean age 47 +/- 12 years, creatinine clearances of 21 +/- 12 ml/min)
Study: 7812699
Drug: Immunoscintigraphy (IS)
Normalized name: IS-5MN
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immunoscintigraphy (IS) using iodine‐131 anti‐carcinoembryonic antigen (CEA) and anti‐carbohydrate 19‐9 (CA 19-9) monoclonal antibody
Study: 30845365
Drug: Alendronic acid
Normalized name: Alendronic Acid
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronic acid 70 mg once weekly (n=215)
Study: 30427494
Drug: 40% mangosteen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% mangosteen peel extract gel (MP-40)
Study: 30427494
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (negative-control)
Study: 30427494
Drug: Bleaching +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleaching + no treatment (positive-control)
Study: 30427494
Drug: 10% mangosteen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% mangosteen peel extract gel (MP-10)
Study: 30427494
Drug: 20% mangosteen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% mangosteen peel extract gel (MP-20)
Study: 3045027
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of cisapride i.v.